Význam gastrointestinální flóry v léčbě nádorů pomocí checkpoint inhibitorů

Stáhnout PDF English version

Autoři: L. Mendoza
Působiště autorů: IQVIA Solutions a. s.
Vyšlo v časopise: Klin Onkol 2018; 31(6): 465-467
Kategorie: Dopis redakci
doi: https://doi.org/10.14735/amko2018465

Souhrn

Autor deklaruje, že v souvislosti s předmětem studie nemá žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Obdrženo: 4. 10. 2018

Přijato: 14. 10. 2018

Zdroje

1. Qin L, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464(7285): 59– 65. doi: 10.1038/ nature08821.

2. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009; 15(13): 1546– 1558.

3. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001; 292(5519): 1115– 1158.

4. Viaud S, Saccheri F, Mignot G et al. The intestinal microbioa modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342(6161): 971– 976. doi: 10.1126/ science.1240537.

5. Yu AQ, Li L. The potential role of probiotics in cancer prevention and treatment. Nutr Cancer 2016; 68(4): 535– 544. doi: 10.1080/ 01635581.2016.1158300.

6. Kechagia M, Basoulis D, Konstantopoulou S et al. Health benefits of probiotics: a review. Nutr 2013; 2013: 481651. doi: 10.5402/ 2013/ 481651.

7. Bron PA, Tomita S, Mercenies A et al. Cell surface-associated compounds of probiotic lactobacilli sustain the strain-specific dogma. Curr Opin Microbiol 2013; 16(3): 262– 269. doi: 10.1016/ j.mib.2013.06.001.

8. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4): 252– 264. doi: 10.1038/ nrc3239.

9. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27(4): 450– 461. doi: 10.1016/ j.ccell.2015.03.001.

10. Sharma P, Hu-Lieskovan S, Wargo JA et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017; 168(4): 707– 723. doi: 10.1016/ j.cell.2017.01.017.

11. Ribas A, Hamid O, Daud A et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016; 315(15): 1600– 1609. doi: 10.1001/ jama.2016.4059.

12. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372(21): 2018– 2028. doi: 10.1056/ NEJMoa1501824.

13. Syn NL, Teng MW, Mok TS et al. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 2017; 18(12): e731– e741. doi: 10.1016/ S1470-2045(17)30607-1.

14. Shono Y, Docampo MD, Peled JU et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med 2016; 8(339): 339ra71. doi: 10.1126/ scitranslmed.aaf2311.

15. Peled JU, Devlin SM, Staffas A et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncol 2017; 35(15): 1650– 1659. doi: 10.1200/ JCO. 2016.70.3348.

16. Routy B, Le Chatelier E, Derosa L et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018; 359(6371): 91– 97. doi: 10.1126/ science.aan3706.

17. Gopalakrishnan V, Spencer CN, Nezi L et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018; 359(6371): 97– 103. doi: 10.1126/ science.aan4236.

18. Derosa L, Hellmann MD, Spaziano M et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 2018; 29(6): 1437– 1444. doi: 10.1093/ annonc/ mdy103.

19. Derosa L, Routy B, Enot D et al. Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. J Clin Oncol 2017; 35 (Suppl.): abstr. 462.

20. Vétizou M, Pitt JM, Daillère R et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350(6264): 1079– 1084. doi: 10.1126/ science.aad1329.

21. Chaput N, Lepage P, Coutzac C et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 2017; 28(6): 1368– 1379. doi: 10.1093/ annonc/ mdx108.

22. Pitt JM, Vétizou M, Gomperts Boneca I et al. Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. Oncoimmunology 2016; 6(1): e1132137. doi: 10.1080/ 2162402X.2015.1132137.

23. Sivan A, Corrales L, Hubert N et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350(6264): 1084– 1089. doi: 10.1126/ science.aac4255.